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letter to editorHemophagocytic
lymphohistiocytosis in
a patient with dengue
infection showed positivity for IgM. BM patient fulﬁlled the criteria on theTo the Editor: Hemophagocytic
lymphohistiocytosis (HLH) is a
life-threatening disease of the
immune system. Primary HLH is
an autosomal recessive disorder
while the acquired form occurs
due to overwhelming immunologic
activation, secondary to systemic
infection, immunodeﬁciency, or
underlying malignancy.1 Herpes
viruses have been documented as
common precipitating agents of
secondary HLH.1 The dengue virus
infection, however, has been reported
as a cause ofHLHinonly ahandful of
cases in the literature.2 We report a
case of a young male who developed
HLH secondary to dengue infection.CASE REPORT
A 26-year-old male presented
in emergency department with
two weeks’ history of intermittent
fever with chills, vomiting, poor
appetite, and lassitude. There was
history of black, tarry stools a
week before reporting to our hos-
pital. At the time of admission,
he was febrile, toxic, and drowsy.
Pulse was 120 beats/min, and
blood pressure 100/50 mmHg.
He had facial pufﬁness, yellowish
sclera, and conjunctival haemor-
rhages. Chest examination showed
bilateral basal crepitations. Abdo-
men was distended, and shifting
dullness was elicited. His hemoglo-
bin was 9.6 g/dl, white blood cell
count (WBCs) 1.0 · 109/l and
platelets 62 · 109/l. His blood
urea, creatinine, total bilirubin,
alanine transaminase, lactate dehy-
drogenase, and D-dimers were
raised.Hematol Oncol Stem Cell Ther 8(4) Fourth Quarter 20The next day, dengue serology
and bone marrow (BM) examina-
tion were advised. Dengue serology
revealed marked hemophagocytosis
(Fig. 1). Possibility of HLH sec-
ondary to dengue infection was
considered and serum triglycerides
and ferritin were requested. Serum
triglycerides were 3.2 mmol/l (ref-
erence range: 0.4–1.6) and ferritin
was 24,459 lg/l (range: 20–
250 ng/ml). In the meantime, the
patient was managed with intra-
venous ﬂuids, broad-spectrum
antibiotics and ventilatory support.
His condition continued to worsen
and he expired on the third day of
admission.
DISCUSSION
Dengue fever (DF) is an acute,
mostly self-limiting, mosquito
borne systemic viral infection.
Dengue virus (DENV), a single-
stranded, positive-sense RNA
virus, has four serotypes desig-
nated as DENV-1 to 4. Although
most dengue infections are asymp-
tomatic, the disease may present in
a variety of clinical manifestations,
ranging from mild febrile illness to
severe fatal disease.3 HLH does
not feature in the World Health
Organization’s guidelines on den-
gue, either in the disease classiﬁca-
tion or in the complications.3
However, during the past two dec-
ades, HLH has been reported
occasionally as a complication of
dengue.2
Clinical features of HLH are
nonspeciﬁc and similar to those
of severe dengue. Laboratory fea-
tures of secondary HLH include
cytopenias; deranged liver function
tests, coagulopathies; raised serum
ferritin; lactate dehydrogenase and
triglycerides; and BM hemophago-15cytosis.1 Diagnosis of HLH is
based on the diagnostic criteria of
the Histiocyte Society.1 Our
basis of having fever, cytopenia,
raised ferritin and triglycerides,
and BM haemophagocytosis.
Pro-inﬂammatory cytokines
play an important role in the
pathogenesis of dengue infection
as well as HLH, thus forming
the pathogenetic link between the
two. In dengue infections, the
release of acute-phase response
proteins and cytokines, such as
tumor necrosis factor-a (TNF-a),
c-interferon, interleukin(IL)-2,
IL-6, IL-8 and IL-10 from the
virus-infected cells, have a role in
the immuno-pathogenesis of the
disease.4 In HLH, the manifesta-
tions of the disease are due to
increased secretion of pro-inﬂam-
matory cytokines such as c-inter-
feron, TNF-a, IL-6, IL-10, and
the macrophage colony stimulating
factor.
The management of patients
with secondary HLH consists of
treatment of the triggering cause,
supportive management, corticos-
teroids and, if required, chemother-
apy.5 Our patient was admitted in
moribund condition and died on
the third day of admission soon
after the diagnosis, before treat-
ment for HLH could be started.
Although rare, HLH does
appear to form part of the spec-
trum of clinical manifestations of
dengue infection. Early recognition
of HLH in dengue infection is
important because it warrants
speciﬁc treatment. In view of the
multiple case reports on HLH in
dengue infection, there is perhaps
a need to incorporate HLH in
the guidelines for the diagnosis
and classiﬁcation of dengue
infection.189
Figure 1. Bone marrow smear of the patient (Leishman-stained) showing a hemophagocytic cell.
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